3α,7α,12α-trihydroxy-24-methyl-5β-cholan-24-one | 76937-70-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3α,7α,12α-trihydroxy-24-methyl-5β-cholan-24-one
• 英文别名: 3α,7α,12α-Trihydroxy-24-methyl-5β-cholan-24-on；26,27-Dinor-3alpha,6alpha,12alpha-trihydroxy-5beta-cholestan-24-one；(5R)-5-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]hexan-2-one
• CAS: 76937-70-7
• 化学式: C₂₅H₄₂O₄
• 分子量: 406.606
• InChiKey: XZKHOQXQDMYABL-BCWNTCASSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3α,7α,12α-trihydroxy-24-methyl-5β-cholan-24-one 生成 5β,24ξH-ergostane-3α,7α,12α-triol
  参考文献：
  名称：

  Seno, Proceedings of the Japan Academy, 1955, vol. 31, p. 733,734

  摘要：

  DOI：
• 作为产物：
  描述：

  24-bromomethyl-3α,7α,12α-tris-formyloxy-5β-cholan-24-one 在 溶剂黄146 、 锌 作用下， 生成 3α,7α,12α-trihydroxy-24-methyl-5β-cholan-24-one
  参考文献：
  名称：

  Kazuno et al., Proceedings of the Japan Academy, 1952, vol. 28, p. 416,417

  摘要：

  DOI：

文献信息

• FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
  申请人：Sarepta Therapeutics, Inc.

  公开号：US20140330006A1

  公开（公告）日：2014-11-06

  Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

  提供了包含修改的亚单位间连接和/或修改的3'和/或5'-末端基团的功能修饰寡核苷酸类似物。所公开的化合物对于治疗需要抑制蛋白质表达或纠正异常mRNA剪接产物以产生有益治疗效果的疾病是有用的。
• Cationic Steroid Antimicrobial Compositions and Methods of Use
  申请人：Savage B. Paul

  公开号：US20070190067A1

  公开（公告）日：2007-08-16

  The invention provides methods for decreasing or inhibiting human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) in vitro, ex vivo or in vivo, or an adverse side effect of human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).

  这项发明提供了用于在体外、体外或体内减少或抑制人类免疫缺陷病毒（HIV）感染或病理发生（例如，疾病）、在体外、体外或体内与人类免疫缺陷病毒（HIV）感染或病理发生（例如，疾病）相关的症状或病理、或在体外、体外或体内人类免疫缺陷病毒（HIV）感染或病理发生（例如，疾病）的不良副作用的方法。在一种实施方式中，该发明的方法包括使用一种发明化合物（例如，阳离子类固体抗菌剂或CSA）治疗受试者。
• Cationic Steroid Microbial Compositions and Methods of Use
  申请人：Savage B. Paul

  公开号：US20070191322A1

  公开（公告）日：2007-08-16

  The invention relates to methods for decreasing or inhibiting influenza virus infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with influenza infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of influenza infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).

  该发明涉及减少或抑制体外、体内或体外细胞的流感病毒感染或发病机制，体外、体内或体外与流感感染或发病机制相关的症状或病理学，或体外、体内或体外流感感染或发病机制的不良副作用的方法。在一种实施方式中，该发明的方法包括使用一种发明化合物（例如，阳离子类固醇抗微生物药物或CSA）治疗受试者。
• APOLIPOPROTEIN NANODISCS WITH TELODENDRIMER
  申请人：The Regents of The University of California

  公开号：US20130165636A1

  公开（公告）日：2013-06-27

  The present invention provides a nanodisc with a membrane scaffold protein. The nanodisc includes a membrane scaffold protein, a telodendrimer and a lipid. The membrane scaffold protein can be apolipoprotein. The telodendrimer has the general formula PEG-L-D-(R) n , wherein D is a dendritic polymer; L is a bond or a linker linked to the focal point group of the dendritic polymer; each PEG is a poly(ethylene glycol) polymer; each R is and end group of the dendritic polymer, or and end group with a covalently bound hydrophobic group, hydrophilic group, amphiphilic compound, or drug; and subscript n is an integer from 2 to 20. Cell free methods of making the nanodiscs are also provided.

  本发明提供了一种具有膜支架蛋白的纳米盘。该纳米盘包括膜支架蛋白、端酯聚合物和脂质。膜支架蛋白可以是载脂蛋白。端酯聚合物具有通式PEG-L-D-(R)n，其中D是树枝状聚合物；L是与树枝状聚合物的焦点基团连接的键或连接物；每个PEG是聚乙二醇聚合物；每个R是树枝状聚合物的末端基团，或具有共价结合的疏水基团、亲水基团、两性化合物或药物的末端基团；下标n是2到20之间的整数。还提供了制备纳米盘的无细胞方法。
• OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
  申请人：Sarepta Therapeutics, Inc.

  公开号：US20150073140A1

  公开（公告）日：2015-03-12

  Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

  提供了包含修饰的亚基间连接和/或修饰的3'和/或5'-末端基团的寡核苷酸类似物。所披露的化合物对于治疗需要抑制蛋白质表达或纠正异常mRNA剪接产物以产生有益治疗效果的疾病是有用的。